The purpose of this study is to study the safety and effects of two new immunotherapies aimed at achieving and maintaining tumor shrinkage in patients with non-microsatellite stable colorectal cancer without liver metastases.

Botensilimab (also known as AGEN1181) and balstilimab (also known as AGEN2034) are both experimental drugs, which means that neither have been approved by the U.S. Food and Drug Administration (FDA).

The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with multiple myeloma (MM) who have had an autologous hematopoietic stem cell transplant (AHCT) and have already received lenalidomide as maintenance therapy.
   
The study drug iberdomide is designed to target and destroy proteins that produce myeloma cancer cells. By destroying these proteins, iberdomide may prevent the cancer from returning or getting worse. This research study is being done because currently there is no effective treatment for this type of condition.

This clinical trial is for adult participants 50 years of age or older who are not currently suspected of having cancer and do not have a personal history of invasive solid tumor or hematologic malignancy (blood cancer) within the past 3 years.
   

This clinical trial is for adult participants who have metastatic pancreatic cancer and have been given prior chemotherapy with FOLFIRINOX (5FU + leucovorin + irinotecan + oxaliplatin).

The purpose of this study is to test the safety of a study drug called KRT-232 (AMG 232) when used in combination with a standard treatment regimen for relapsed or refractory multiple myeloma. The standard treatment is with the drugs carfilzomib, lenalidomide, and dexamethasone (KRd).

The purpose of this study is to test the effectiveness of the drugs cabozantinib with nivolumab and ipilimumab in rare genitourinary (GU) cancers that have no standard treatment options.

Rhabdomyosarcoma (RMS) is a type of cancer that occurs in the soft tissues of the body like the muscles. This study will compare the safety and effect of adding vinorelbine to vincristine, dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high risk rhabdomyosarcoma (RMS). High risk refers to cancer that is likely to recur (come back) after treatment or spread to other parts of the body.

This study is for male and female children, adolescents, and young adults under the age of 25 who have been diagnosed with Chronic Myeloid Leukemia (CML) that is in the earliest phase known as the chronic phase. Chronic phase means that the level of disease is very low and is often called molecular remission.  To keep the CML at this low level, people typically take a type of drug called a tyrosine kinase inhibitor (TKI), such as imatinib, dasatinib, and nilotinib every day.
   

The purpose of this study is to compare the usual treatment to using duvelisib or CC-486 plus the usual treatment for patients with CD30 negative peripheral T-Cell lymphoma that has not been previously treated. The addition of duvelisib or CC-486 (azacitidine) to the usual treatment may or may not increase the chance of the cancer going into remission.   

The purpose of this study is to test the safety of a drug called M3814 (peposertib) in combination with a specific type of radiation therapy (hypofractionated radiation) in patients with locally advanced pancreatic cancer. This study will test different doses of M3814 to see which dose is safer for people when combined with hypofractionated radiation.